Inmune Bio Inc (INMB)

Apr 01, 2025

INmune Bio Presents MINDFuL Trial Data At AD/PD 2025 - Nasdaq

Apr 01, 2025

Apr 01, 2025

INmune Bio Presents Baseline Data From MINDFuL Phase II Trial In Early Alzheimer's Disease - Nasdaq

Apr 01, 2025

Apr 01, 2025

INmune Bio presents early Alzheimer’s trial data at AD/PD - Investing.com

Apr 01, 2025

Apr 01, 2025

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times

Apr 01, 2025

Apr 01, 2025

INmune Bio presents early Alzheimer’s trial data at AD/PD By Investing.com - Investing.com UK

Apr 01, 2025

Apr 01, 2025

Promising Patient Profile Emerges in Major Alzheimer's Drug Trial: 69% Carry Key Risk Gene - Stock Titan

Apr 01, 2025

Mar 31, 2025

Raymond James maintains INmune Bio stock with $23 target By Investing.com - Investing.com Australia

Mar 31, 2025

Mar 31, 2025

Raymond James maintains INmune Bio stock with $23 target - Investing.com India

Mar 31, 2025

Mar 31, 2025

Raymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World

Mar 31, 2025

Mar 30, 2025

INmune Bio anticipates Alzheimer's trial results within 100 days while advancing therapeutic platforms - MSN

Mar 30, 2025

Mar 29, 2025

INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025

Mar 28, 2025

INmune Bio (INMB) Eyes Landmark Developments in 2024 Amid Rising Financial Commitments - GuruFocus

Mar 28, 2025

Mar 28, 2025

Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus - Investing.com Australia

Mar 28, 2025

Mar 28, 2025

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategi - GuruFocus.com

Mar 28, 2025

Mar 28, 2025

INmune Bio Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 28, 2025

Mar 27, 2025

Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

INmune Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

INmune Bio Inc Reports Q4 EPS of -$0.53 and Revenue of $0.01 Mil - GuruFocus.com

Mar 27, 2025

Mar 27, 2025

INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq

Mar 27, 2025

Mar 27, 2025

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - TradingView

Mar 27, 2025

Mar 27, 2025

INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured - Stock Titan

Mar 27, 2025

Mar 27, 2025

(INMB) On The My Stocks Page - news.stocktradersdaily.com

Mar 27, 2025

Mar 26, 2025

What to Expect from INmune Bio's Earnings - Benzinga

Mar 26, 2025

Mar 24, 2025

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 - The Manila Times

Mar 24, 2025

Mar 24, 2025

INmune Bio Sets Key Q4 Earnings Date: Critical Updates Expected for Clinical Pipeline - Stock Titan

Mar 24, 2025

Mar 21, 2025

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha

Mar 21, 2025

Mar 20, 2025

INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 20, 2025

Mar 18, 2025

INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results (INMB) - Seeking Alpha

Mar 18, 2025

Mar 13, 2025

Analysts Set INmune Bio, Inc. (NASDAQ:INMB) Target Price at $22.80 - Defense World

Mar 13, 2025

Mar 11, 2025

INmune Bio, Inc. (NASDAQ:INMB) Position Lifted by Rhumbline Advisers - Defense World

Mar 11, 2025

Mar 09, 2025

Protalix BioTherapeutics (NYSE:PLX) and INmune Bio (NASDAQ:INMB) Head-To-Head Review - The AM Reporter

Mar 09, 2025

Mar 06, 2025

(INMB) Investment Analysis - Stock Traders Daily

Mar 06, 2025

Mar 04, 2025

INmune Bio Reports Promising Phase I/II Trial Results - TipRanks

Mar 04, 2025

Mar 03, 2025

PMGC Holdings Ends License Agreement with INmune Bio By Investing.com - Investing.com South Africa

Mar 03, 2025

Mar 03, 2025

PMGC Holdings Ends License Agreement with INmune Bio - Investing.com

Mar 03, 2025

Mar 03, 2025

Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025 - MSN

Mar 03, 2025

Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025

Feb 27, 2025

Is INmune Bio (NASDAQ:INMB) A Risky Investment? - Simply Wall St

Feb 27, 2025

Feb 24, 2025

INmune Delivers Impressive 100% Gain In Just 3 MonthsIs There More Room To Run? - RTTNews

Feb 24, 2025

Feb 23, 2025

Learn to Evaluate (INMB) using the Charts - Stock Traders Daily

Feb 23, 2025

Feb 21, 2025

INmune Bio, Inc. to Host Earnings Call - ACCESS Newswire

Feb 21, 2025

Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% - Yahoo Finance

Feb 20, 2025

Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter

Feb 20, 2025

Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update - MarketBeat

Feb 20, 2025

Feb 18, 2025

INmune Bio, Inc. (NASDAQ:INMB) Sees Significant Growth in Short Interest - Defense World

Feb 18, 2025

Feb 18, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Analysts - Defense World

Feb 18, 2025

Feb 16, 2025

INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says - MarketBeat

Feb 16, 2025

Feb 16, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Brokerages - Defense World

Feb 16, 2025